NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Ampio Pharmaceuticals, Inc. (NYSE: AMPE) resulting from allegations that Ampio may have issued materially misleading business information to the investing public.
On August 7, 2018, during aftermarket hours, Ampio filed a Form 8-K with the SEC providing a regulatory update on the FDA’s review of Ampion, including the AP-003-A and AP-003-C trials. Ampio disclosed that it met with the FDA in July 2018 and received a response letter thereto, which stated that “as a single trial[,] the AP-003-A study alone does not appear to provide sufficient evidence of effectiveness to support [the Biologics License Application].” The FDA further provided that “the FDA does not consider the AP-003-C trial to be an adequate and well-controlled clinical trial.” On this news, shares of Ampio’s stock fell sharply during intraday trading on August 8, 2018.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Ampio investors. If you purchased shares of Ampio please visit the firm’s website at http://www.rosenlegal.com/cases-1397.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.
Attorney Advertising. Prior results do not guarantee a similar outcome.